Sign up for our daily Newsletter and stay up to date with all the latest news!

Subscribe I am already a subscriber

You are using software which is blocking our advertisements (adblocker).

As we provide the news for free, we are relying on revenues from our banners. So please disable your adblocker and reload the page to continue using this site.
Thanks!

Click here for a guide on disabling your adblocker.

Sign up for our daily Newsletter and stay up to date with all the latest news!

Subscribe I am already a subscriber

Koppert announces €800,000 investment into Amoéba

Koppert has announced its intention to invest €800,000 in Amoéba S.A. This equity investment reinforces the companies' long-term collaboration, following the recently signed five-year exclusive global distribution agreement for Amoéba's biofungicide solution.

Advancing sustainable agriculture through partnership
The biofungicide solution is based on the lysate of the amoeba Willaertia magna C2c, and is designed to combat fungal diseases such as Downy Mildew and Powdery Mildew in high-value crops like grapes and vegetables. The product introduces a novel mode of action and fills a critical gap in the current biocontrol offering, particularly in Europe and the United States.

The EU has already approved the active substance in Q2 2024, with full product registrations expected by early 2026. Under the agreement, Koppert will distribute the product under its own brand across 18 European countries and the U.S., with expansion discussions for Brazil underway.

Strengthening future market success
The €800,000 investment is part of a broader capital increase by Amoéba aimed at funding production scale-up, working capital, and regulatory development. This step strengthens the strategic alignment between the two companies and supports Amoéba's operational readiness to deliver on its commercial commitments.

"This investment underlines our deep confidence in Amoéba's innovative approach and the strong commercial potential of this biofungicide," says Martin Koppert, Chief Business Officer of Koppert. "We are committed to accelerating the adoption of biological solutions that help growers transition to more sustainable practices."

"Koppert's support both commercially and now financially, validates the long-term value of our biocontrol technology," adds Jean-François Doucet, CEO of Amoéba. "Together, we are unlocking a new chapter in sustainable crop protection."

The partnership highlights both companies' shared vision to advance biological alternatives and make a positive impact on agriculture worldwide.

For more information:
Amoéba
amoeba-nature.com/en/

Koppert
[email protected]
www.koppert.com

Related Articles → See More